Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

被引：13
作者：
Li, B. T. [1 ]
Planchard, D. [2 ]
Goto, K. [3 ]
Smit, E. F. [4 ]
De langen, J. [5 ]
Goto, Y. [6 ]
Ninomiya, K. [7 ]
Kubo, T. [8 ]
Perol, M. [9 ]
Felip, E. [10 ]
Hayashi, H. [11 ]
Nakagawa, K. [11 ]
Shimizu, J. [12 ]
Nagasaka, M. [13 ]
Pereira, K. M. C. [14 ]
Taguchi, A. [15 ]
Ali, A. [16 ]
Karnoub, M.
Yonemochi, R. [14 ]
Janne, P. A. [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[2] Gustave Roussy, Med Oncol, Villejuif, France
[3] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[4] LUMC Leiden Univ, Dept Pulm Dis, Med Ctr, Leiden, Netherlands
[5] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[6] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[7] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan
[8] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[9] Leon Berard Canc Ctr, Med Oncol, Lyon, France
[10] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[11] Kindai Univ Hosp, Dept Med Oncol, Osakasayama, Japan
[12] Aichi Canc Ctr Hosp, Thorac Oncol, Nagoya, Aichi, Japan
[13] Univ Calif Irvine, Med, Sch Med, Orange, CA USA
[14] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA
[15] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan
[16] Dauchi Sankyo Europe GmbH, Global Oncol Med Affairs, Munich, Germany
[17] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1321MO
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Trastuzumab deruxtecan (T-DXd) in patients with HER2+metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.
    Jerusalem, Guy Heinrich Maria
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Gonzalez, Xavier
    Hall, Peter S.
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R. C.
    Sagara, Yasuaki
    Tokunaga, Eriko
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb C.
    Perrin, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
    Qi, Zhenhao
    Tokuhiro, Shinya
    Odegaard, Justin I.
    Wienke, Sara
    Karnoub, Maha
    Feng, Wenqin
    Shiga, Ryota
    Smit, Egbert F.
    Goto, Yasushi
    De Langen, Adrianus J.
    Goto, Koichi
    Pereira, Kaline
    Khambata-Ford, Shirin
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2025, 27 (02) : 119 - 129
  • [23] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Cobbina, Enoch
    Cheng, Shen
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
    Makker, V.
    Lee, J-Y.
    Oh, D-Y.
    Oaknin, A.
    Puvvada, S. D.
    Cecchi, F.
    Mcewen, R.
    Michelini, F.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
  • [25] Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
    Planchard, D.
    Brahmer, J. R.
    Yang, J. C-H.
    Kim, H. R.
    Li, R. K.
    Han, J-Y.
    Cortinovis, D. L.
    Runglodvatana, Y.
    Nakajima, E.
    Ragone, A.
    Winter, M.
    Gustavson, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [26] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    Smit, Egbert F.
    Felip, Enriqueta
    Uprety, Dipesh
    Nagasaka, Misako
    Nakagawa, Kazuhiko
    Rodriguez, Luis Paz-Ares
    Pacheco, Jose M.
    Li, Bob T.
    Planchard, David
    Baik, Christina
    Goto, Yasushi
    Murakami, Haruyasu
    Saltos, Andreas
    Pereira, Kaline
    Taguchi, Ayumi
    Cheng, Yingkai
    Yan, Qi
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    LANCET ONCOLOGY, 2024, 25 (04) : 439 - 454
  • [27] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)
    Meric-Bernstam, Funda
    Kim, Seung Tae
    Parinyanitikul, Napa
    Moreno, Alberto
    Lin, Chia-Chi
    Gornastolev, Dmitry
    Chindaprasirt, Jarin
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jassem, Jacek
    Harrison, Michelle L.
    Ostwal, Vikas S.
    Michelini, Flavia
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Puvvada, Soham D.
    Gan, Hui Kong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 41, pg 4852, 2023)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 485 - 485
  • [29] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
    Raghav, Kanwal Pratap Singh
    Siena, Salvatore
    Takashima, Atsuo
    Kato, Takeshi
    Van den Eynde, Marc
    Di Bartolomeo, Maria
    Komatsu, Yoshito
    Kawakami, Hisato
    Peeters, Marc
    Andre, Thierry
    Lonardi, Sara
    Yamaguchi, Kensei
    Tie, Jeanne
    Castro, Cristina Gravalos
    Strickler, John H.
    Barrios, Daniel
    Yan, Qi
    Kamio, Takahiro
    Kobayashi, Kojiro
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
    Li, B. T.
    Meric-Bernstam, F.
    Bardia, A.
    Naito, Y.
    Siena, S.
    Aftimos, P. G.
    Anderson, I.
    Curigliano, G.
    De Miguel Luken, M. J.
    Kalra, M.
    Oh, D-Y.
    Park, J. O.
    Postel-Vinay, S.
    Rha, S. Y.
    Satoh, T.
    Spanggaard, I.
    Michelini, F.
    Smith, A.
    Machado, K. Kalil
    Saura Manich, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S460
12345